Hoffmann K Martin, Gibril Fathia, Entsuah Laurence K, Serrano Jose, Jensen Robert T
Digestive National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases/Digestive Diseases Branch, Bethesda, Maryland 20892-1804, USA.
J Clin Endocrinol Metab. 2006 Jan;91(1):204-12. doi: 10.1210/jc.2005-1349. Epub 2005 Oct 25.
Multiple endocrine neoplasia type 1 (MEN1) patients frequently develop Zollinger-Ellison syndrome (MEN1/ZES). Although esophageal reflux symptoms are common in these patients, little is known about long-term occurrence of severe peptic esophageal disease including strictures and Barrett's esophagus (BE).
The objective of the study was to prospectively analyze the frequency of severe peptic esophageal disease in ZES patients with and without MEN1.
The study was conducted at a tertiary care research center.
Two hundred ninety-five patients (80 = MEN1/ZES, 215 = sporadic ZES) participated in a prospective study.
Assessment of MEN1, acid hypersecretion, upper gastrointestinal endoscopy/biopsies, and tumor status were measured initially and at each follow-up. Esophageal manometry was performed in 89 patients. Frequency and type of esophageal disease were correlated with clinical/laboratory/tumoral features of ZES/MEN1.
In MEN1/ZES patients, esophageal stricture was 3-fold higher, BE 5-fold higher, and dysplasia 8-fold higher, and one patient died of esophageal adenocarcinoma. Esophageal symptoms were more frequent or severe in MEN1/ZES, but known risk factors for severe esophageal disease and ZES-specific features did not differ between MEN1/ZES and sporadic ZES. In MEN1/ZES, the onset of ZES was 10 yr earlier, and H2-antagonists were used longer and at lower doses. MEN1/ZES patients with esophageal disease differed from those without in that ZES diagnosis was delayed longer, esophageal symptoms were more frequent or severe, hiatal hernias were more frequent, esophagitis or pyloric scarring was more common, basal acid output was higher, and hyperparathyroidism was underdiagnosed.
This study shows that MEN1/ZES patients have a higher incidence of severe esophageal disease including the premalignant condition BE and identifies factors important for their pathogenesis that need to be incorporated into their long-term treatment.
1型多发性内分泌腺瘤病(MEN1)患者常发生卓-艾综合征(MEN1/ZES)。虽然这些患者中食管反流症状很常见,但对于包括狭窄和巴雷特食管(BE)在内的严重消化性食管疾病的长期发生率知之甚少。
本研究的目的是前瞻性分析伴有和不伴有MEN1的ZES患者中严重消化性食管疾病的发生率。
该研究在一家三级医疗研究中心进行。
295例患者(80例 = MEN1/ZES,215例 = 散发性ZES)参与了一项前瞻性研究。
最初及每次随访时均对MEN1、胃酸分泌过多、上消化道内镜检查/活检以及肿瘤状态进行评估。89例患者进行了食管测压。食管疾病的发生率和类型与ZES/MEN1的临床/实验室/肿瘤特征相关。
在MEN1/ZES患者中,食管狭窄发生率高3倍,BE高5倍,发育异常高8倍,1例患者死于食管腺癌。MEN1/ZES患者的食管症状更频繁或更严重,但严重食管疾病的已知危险因素和ZES的特异性特征在MEN1/ZES和散发性ZES之间并无差异。在MEN1/ZES中,ZES发病早10年,H2拮抗剂使用时间更长且剂量更低。患有食管疾病的MEN1/ZES患者与未患食管疾病的患者不同之处在于,ZES诊断延迟更长,食管症状更频繁或更严重,食管裂孔疝更常见,食管炎或幽门瘢痕更普遍,基础胃酸分泌量更高,甲状旁腺功能亢进诊断不足。
本研究表明,MEN1/ZES患者发生包括癌前病变BE在内的严重食管疾病的发生率更高,并确定了对其发病机制重要的因素,这些因素需要纳入其长期治疗中。